Dose-expansion cohorts (DECs) enable investigators to identify potentially effective drugs, for specific patient populations, in a single trial by assessing antitumour activity as early as possible. We discuss how the objectives, design and interpretation of DEC have evolved, and how DECs are changing the landscape of early drug development.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Design considerations for early-phase clinical trials of immune-oncology agents
Journal for ImmunoTherapy of Cancer Open Access 22 August 2018
-
An analysis of common ethical justifications for compassionate use programs for experimental drugs
BMC Medical Ethics Open Access 18 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cannistra, S. Challenges and pitfalls of combining targeted agents in phase I studies. J. Clin. Oncol. 26, 3665–3667 (2008).
Iasonos, A. & O'Quigley, J. Design considerations for dose-expansion cohorts in phase I trials. J. Clin. Oncol. 31, 4014–4021 (2013).
Manji, A. et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J. Clin. Oncol. 31, 4260–4267 (2013).
Motzer, R. J. et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J. Clin. Oncol. 33, 1430–1437 (2015).
O'Quigley, J. & Iasonos, A. Bridging solutions in dose finding problems. Stat. Biopharm. Res. 6, 185–197 (2014).
Onar, A., Kocak, M. & Boyett, J. M. Continual reassessment method vs traditional empirically based design: modifications motivated by phase I trials in pediatric oncology by the pediatric brain tumor consortium. J. Biopharm. Stat. 19, 437–455 (2009).
O'Quigley, J., Hughes, M. D. & Fenton, T. F. Dose-finding design for HIV studies. Biometrics 57, 1018–1029 (2001).
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD–1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
McDermott, D. F. et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol. 33, 2013–2020 (2015).
Iasonos, A. & O'Quigley, J. Working Paper 28: Dose expansion cohorts in phase I trials. Memorial Sloan-Kettering Cancer Center, Deptartment of Epidemiology & Biostatistics Working Paper Series [online], (2014).
Acknowledgements
This work was partially supported by the NIH (grant numbers R01 CA142859 and and P30 CA008748) and The Translational and Integrative Medicine Research Fund at Memorial Sloan Kettering Cancer Center, NY, USA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Iasonos, A., O'Quigley, J. Early phase clinical trials—are dose expansion cohorts needed?. Nat Rev Clin Oncol 12, 626–628 (2015). https://doi.org/10.1038/nrclinonc.2015.174
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.174
This article is cited by
-
Randomised Phase 1 clinical trials in oncology
British Journal of Cancer (2021)
-
An Empirical Investigation of Bayesian Clinical Trial Design in Metastatic Breast Cancer
Therapeutic Innovation & Regulatory Science (2020)
-
Design considerations for early-phase clinical trials of immune-oncology agents
Journal for ImmunoTherapy of Cancer (2018)
-
An analysis of common ethical justifications for compassionate use programs for experimental drugs
BMC Medical Ethics (2016)